Aptose Biosciences (TSE:APS) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$1.89 and traded as high as C$2.32. Aptose Biosciences shares last traded at C$2.32, with a volume of 4,636 shares trading hands.

Analysts Set New Price Targets

Separately, Alliance Global Partners downgraded shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat, Aptose Biosciences has a consensus rating of “Hold”.

Aptose Biosciences Stock Performance

The company has a market cap of C$5.92 million, a price-to-earnings ratio of 3.36 and a beta of -0.05. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The stock’s 50 day moving average price is C$1.89 and its 200 day moving average price is C$1.88.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share (EPS) for the quarter. On average, analysts expect that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.